Most Recent
The former boss of Metigy has been sentenced to nine years behind bars after pleading guilty to misusing company funds and providing false information to investors, who pumped $40 million into the AI start-up.
Fitness support company and NDIS provider WeFlex has paid a $19,800 penalty over social media ads which allegedly made misleading claims about NDIS funding.
RSPCA Queensland has entered into an enforceable undertaking with the Fair Work Ombudsman after underpaying 1,008 staff approximately $4.3 million between February 2017 and September 2023.
A judge has approved a $35 million penalty against HSBC in ASIC’s novel case over the bank's scam protection failures, despite questioning whether the punishment was severe enough given how long the case took to settle.
HSBC has agreed to pay a $35 million penalty in ASIC proceedings after it admitted to serious failures in protecting customers from scams, but a judge is questioning whether the penalty is high enough.
A judge has ordered the former CEO and chief legal officer of Star to pay a combined $1.1 million in penalties for failing to act on "obvious" money laundering risks, but said the fines would have been higher had ASIC not struck a "generous" settlement with other directors.
A former owner of the Ubertas property development group is suing Deloitte Private and Pitcher Partners, alleging they gave her negligent advice that led to an audit and a $12 million tax bill.
The Law Council says asserting legal professional privilege is not "inherently scandalous", ahead of a parliamentary hearing on KPMG's sharing ofclient information, at which law firms Allens and Ashurst are expected to stay mum.
The consumer watchdog has taken fast food burger chain Grill’d to court for allegedly misleading consumers by overstating how much money would go towards planting trees as part of its Tree Day Tuesday promotion.
Swiss drug maker Novartis has lost its bid to have Pharmacor's Valtresto trade mark removed for non use, with an IP Australia delegate finding that an injunction in a fight over the patent for Novartis' heart drug Entresto was an obstacle to using the mark.